You are not logged in.

Request for Proposals - Supply of Intravenous Trastuzumab

Details

Tender Closed
RFx ID : 26286813
Tender Name : Request for Proposals - Supply of Intravenous Trastuzumab
Reference # : A1546983
Open Date : Thursday, 8 September 2022 10:30 AM (Pacific/Auckland UTC+12:00)
Close Date  : Wednesday, 26 October 2022 4:00 PM (Pacific/Auckland UTC+13:00)
Tender Type : Request for Proposals (RFP)
Tender Coverage : Sole Agency  [?]
Categories :
  • 51000000 - Drugs and Pharmaceutical Products
Regions:
  • New Zealand
Exemption Reason : None
Required Pre-qualifications : None
Contact : Pharmac Procurement Team
procurement@pharmac.govt.nz
.
Alternate Physical Delivery Address  :
Alternate Physical Fax Number  :
Agency Address :
Overview

REQUEST FOR PROPOSALS – Supply of intravenous trastuzumab for the New Zealand subsidised market.


This request for proposals (RFP) letter incorporates the following schedules:
· Schedule 1 specifies the pharmaceutical for which Pharmac is requesting proposals and sets out the background to the RFP and the types of proposals sought;
· Schedule 2 describes the process that Pharmac expects to follow in relation to the RFP;
· Schedule 3 sets out information about the estimated size of the current subsidised market for the pharmaceutical; and
· Schedule 4 contains the RFP form in which you are to provide details of your proposal.

Pharmac is not willing to consider proposals involving funded or unfunded pharmaceuticals or related products other than intravenous trastuzumab in a response to this RFP.

The other attachments in addition to the RFP letter on this GETS listing are an editable version of the proposal form and Pharmac's standard terms and conditions for supply of pharmaceuticals that would form the basis of the contract for supply.

If you wish to submit a proposal, you must submit it to Pharmac via the Government Electronic Tenders Service (GETS) (www.gets.govt.nz) no later than 4.00 p.m (NZST) on 19 October 2022.

RFx Outcome

This tender has been awarded.

  • Celltrion Healthcare New Zealand Limited - Suite 13.03, 31 Market Street, Sydney, Sydney, NSW, 2000, AUSTRALIA

Further Award Information:
Te Pātaka Whaioranga (PHARMAC)
Level 9, 40 Mercer Street Wellington
PO Box 10254, Wellington 6143, New Zealand
www.pharmac.govt.nz

Pharmac is pleased to announce the approval of a principal supply agreement progressed through an open RFP for supply of intravenous trastuzumab.

Pharmac has decided to award Principal Supply Status to Celltrion Healthcare New Zealand Limited for the supply of its brand of intravenous trastuzumab (Herzuma) to Te Whatu Ora hospitals. A 5% Alternative Brand Allowance will apply.

You can about the details of the decision and the changes from the contract award on the Pharmac website here: https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/23-08-23-decision-to-widen-access-to-intravenous-trastuzumab-and-change-the-funded-brand/

Please note:

• The agreement eventuating from this process was provisional on consultation and final approval from the Pharmac Board. The notification date is the ‘approval’ or award date.
• The 23 August 2023 award notification is available on the Pharmac website here: https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/23-08-23-decision-to-widen-access-to-intravenous-trastuzumab-and-change-the-funded-brand/
• More information about PSS is available here: https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-to-change-pharmacs-approach-to-competitive-procurement/
• The approximate gross annual expenditure for the intravenous trastuzumab is $35 million.
• Pharmac is committed to sustainable and inclusive procurement that delivers for New Zealand and New Zealanders. Broader outcomes were considered in this process.

Award Date: Wednesday, 23 August 2023 (Pacific/Auckland UTC+12:00)
Date RFx was completed/updated: Friday, 1 September 2023 12:35 PM (Pacific/Auckland UTC+12:00)